Medivation, Inc. (NASDAQ:MDVN)

research

Credit Suisse Says Grit Your Teeth and Buy Biotech

For the second time since late February, a huge run on the momentum, and specifically biotech, names hit the market last week. Again, the biotech benchmark took a huge 4% ...
Read Full Story »
Biotechnology word cloud

Short Sellers Find Renewed Interest in Biotech Stocks

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. After retreating from many of these stocks in the previous two periods, short sellers returned ...
Read Full Story »
DNA

Ten Top Biotech Merger and Partnership Candidates

One of the ways the big pharmaceutical and biotechnology firms grow their business is through partnerships and acquisitions. That was never more in focus than Thursday when Pfizer lost its ...
Read Full Story »
Biotechnology word cloud

Short Sellers Retreat From Biotech Stocks Again

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Stocks in this industry continue to be hot, but short sellers shied away from many ...
Read Full Story »
DNA

Dendreon Finds New, Long Overdue Lifeblood

Shares of Dendreon Corp. (NASDAQ: DNDN) moved higher Monday after the biotech company said it will start to market Provenge, its prostate-cancer drug, in Europe this year. The announcement came ...
Read Full Story »
Stock Split Image

Five Huge Sell Ratings After News: Tesla, InterMune and More

The higher the market goes, the more likely analysts are to pull the trigger on names they think are stretched. The problem for analysts: In a hot market, stocks often ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Deckers, InterMune, Medivation, Pan American Silver and More

Stocks are hitting news high, earnings season is winding down and Washington, D.C., seems to no longer be a concern. Investors still worry about buying the top and about the ...
Read Full Story »
biotech

Top Pharma and Biotech Stocks to Buy From Key Investor Conference

The Leerink Global Healthcare conference is in full swing, and the reports coming out highlight what some top analysts on Wall Street already suspected. The rich are getting richer. With ...
Read Full Story »
Biotechnology word cloud

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large cap biotech stocks are poised to beat earnings estimates across ...
Read Full Story »
Pills

UBS Has Nine Biotech Buyout and Merger Candidates

After three years of solid outperformance, most firms on Wall Street that we cover remain very positive on biotechnology as a whole. The analysts at UBS are not only bullish ...
Read Full Story »
biotech

Credit Suisse Offers Top Biotech Stocks to Buy for 2014

Credit Suisse is out and pounding the table that biotechnology cannot be ignored in 2014. Biotech has been the top-performing sector for the past three years, with year-to-date performance up ...
Read Full Story »
biotech

Solid Biotech Stocks With the Best Revenue Growth for 2014

Any time investors look for companies growing sales the most, one area that almost always stands out is the up and coming biotech stocks. After all, sales can grow from ...
Read Full Story »
Merger

Five Prime Takeover Candidates for 2014

Many Wall Street analysts and strategists are forecasting a rise in corporate earnings for the rest of the year and throughout 2014. That is music to the ears of stock ...
Read Full Story »
Bank

UBS Sees Hedge Funds Selling Health Care and Buying Financial and Energy Stocks

The UBS proprietary institutional flow data indicates that hedge funds are increasing exposure to financials and decreasing exposure to health care. Given that health care has outperformed significantly year to ...
Read Full Story »
Amazon.com logo

UBS Makes Changes in Top Stocks to Buy on the U.S. Key Call List

The leading firms on Wall Street maintain a list of their top stocks to buy as their highest conviction calls from the top analysts in the firm. What is somewhat ...
Read Full Story »